Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study
Objective To investigate the safety and efficacy of adjuvant gonadotropin‐releasing hormone agonist (GnRH‐a) treatment followed by maintenance dienogest (DNG) therapy after uterus‐sparing surgery. Methods Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus‐sp...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecology and obstetrics 2023-06, Vol.161 (3), p.751-759 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 759 |
|---|---|
| container_issue | 3 |
| container_start_page | 751 |
| container_title | International journal of gynecology and obstetrics |
| container_volume | 161 |
| creator | Chan, I‐San Hsu, Teh‐Fu Shih, Ying‐Chu Chang, Yen‐Hou Wang, Peng‐Hui Chen, Yi‐Jen |
| description | Objective
To investigate the safety and efficacy of adjuvant gonadotropin‐releasing hormone agonist (GnRH‐a) treatment followed by maintenance dienogest (DNG) therapy after uterus‐sparing surgery.
Methods
Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus‐sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty‐six patients (control group) received adjuvant 6‐month GnRH‐a therapy alone after uterus‐sparing surgery, and 44 patients (maintenance group) received postoperative 6‐month GnRH‐a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow‐up period was 18 months. The study was analyzed using generalized estimating equations.
Results
At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P |
| doi_str_mv | 10.1002/ijgo.14635 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2755578176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2755578176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3295-9eaecc47d7d75582e7df34c59be22a694ed7de4afcd20dd56a2ea59a66784693</originalsourceid><addsrcrecordid>eNp9kUFu1TAURS0Eop-WCQtAHiKkFNuJ4x9mVQWlqFUnnUev9kvqr8QOttMqM5bATthTV1KHXzqsLNmDd-6x5UvIB86OOWPii931_phXdSlfkQ3fqqYoK9W8Jps8ZIUSjTgg72LcMca44vwtOShrKZSoyw35ewnWJXTgNFJj0fkeY6LpFgNMC-38MPh763oKZjffgUu09w6MT8FP1j38_hNwQIgrcevD6B1SyIRdHQEhjZgj0CUMdM7bHHMkThDWQJxDj2Gh1mV7vnlcfLTxKz2hAbM_TqiTvUOqfVYnGtNsliPypoMh4vun85Bcf_92ffqjuLg6Oz89uSh0KRpZNAiodaVMXlJuBSrTlZWWzQ0KAXVTYZ5gBZ02ghkjaxAIsoG6VtuqbspD8mmvnYL_NecfaUcbNQ4DOPRzbEW2SrXlqs7o5z2q85NjwK6dgh0hLC1n7dpPu_bT_usnwx-fvPPNiOYZ_V9IBvgeuLcDLi-o2vOfZ1d76SPaD6R6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755578176</pqid></control><display><type>article</type><title>Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chan, I‐San ; Hsu, Teh‐Fu ; Shih, Ying‐Chu ; Chang, Yen‐Hou ; Wang, Peng‐Hui ; Chen, Yi‐Jen</creator><creatorcontrib>Chan, I‐San ; Hsu, Teh‐Fu ; Shih, Ying‐Chu ; Chang, Yen‐Hou ; Wang, Peng‐Hui ; Chen, Yi‐Jen</creatorcontrib><description>Objective
To investigate the safety and efficacy of adjuvant gonadotropin‐releasing hormone agonist (GnRH‐a) treatment followed by maintenance dienogest (DNG) therapy after uterus‐sparing surgery.
Methods
Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus‐sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty‐six patients (control group) received adjuvant 6‐month GnRH‐a therapy alone after uterus‐sparing surgery, and 44 patients (maintenance group) received postoperative 6‐month GnRH‐a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow‐up period was 18 months. The study was analyzed using generalized estimating equations.
Results
At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P < 0.001), hemoglobin level (P = 0.004), and uterine volume (P = 0.004) from baseline to 18 months after uterus‐sparing surgery. The symptom recurrence rate was significantly lower in the maintenance group than in the control group (4.6% vs. 37.0%, P < 0.001).
Conclusions
The findings of this study suggest that combinatorial treatment with GnRH‐a (adjuvant treatment) and DNG (maintenance therapy) represents a safe and effective short‐term therapy after uterus‐sparing surgery for adenomyosis.
Synopsis
Maintenance DNG therapy following adjuvant GnRH‐a treatment after uterus‐sparing surgery was identified as an effective therapy for symptom control and prevention of recurrent adenomyosis.</description><identifier>ISSN: 0020-7292</identifier><identifier>EISSN: 1879-3479</identifier><identifier>DOI: 10.1002/ijgo.14635</identifier><identifier>PMID: 36527263</identifier><language>eng</language><publisher>United States</publisher><subject>adenomyoma ; adenomyosis ; Adenomyosis - drug therapy ; Adenomyosis - surgery ; dienogest ; Female ; GnRH agonist ; Gonadotropin-Releasing Hormone ; Humans ; maintenance therapy ; Retrospective Studies ; Uterus - surgery ; uterus‐sparing surgery</subject><ispartof>International journal of gynecology and obstetrics, 2023-06, Vol.161 (3), p.751-759</ispartof><rights>2022 International Federation of Gynecology and Obstetrics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3295-9eaecc47d7d75582e7df34c59be22a694ed7de4afcd20dd56a2ea59a66784693</citedby><cites>FETCH-LOGICAL-c3295-9eaecc47d7d75582e7df34c59be22a694ed7de4afcd20dd56a2ea59a66784693</cites><orcidid>0000-0002-6074-5915 ; 0000-0002-6048-8541 ; 0000-0002-2982-4500</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijgo.14635$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijgo.14635$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36527263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, I‐San</creatorcontrib><creatorcontrib>Hsu, Teh‐Fu</creatorcontrib><creatorcontrib>Shih, Ying‐Chu</creatorcontrib><creatorcontrib>Chang, Yen‐Hou</creatorcontrib><creatorcontrib>Wang, Peng‐Hui</creatorcontrib><creatorcontrib>Chen, Yi‐Jen</creatorcontrib><title>Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study</title><title>International journal of gynecology and obstetrics</title><addtitle>Int J Gynaecol Obstet</addtitle><description>Objective
To investigate the safety and efficacy of adjuvant gonadotropin‐releasing hormone agonist (GnRH‐a) treatment followed by maintenance dienogest (DNG) therapy after uterus‐sparing surgery.
Methods
Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus‐sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty‐six patients (control group) received adjuvant 6‐month GnRH‐a therapy alone after uterus‐sparing surgery, and 44 patients (maintenance group) received postoperative 6‐month GnRH‐a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow‐up period was 18 months. The study was analyzed using generalized estimating equations.
Results
At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P < 0.001), hemoglobin level (P = 0.004), and uterine volume (P = 0.004) from baseline to 18 months after uterus‐sparing surgery. The symptom recurrence rate was significantly lower in the maintenance group than in the control group (4.6% vs. 37.0%, P < 0.001).
Conclusions
The findings of this study suggest that combinatorial treatment with GnRH‐a (adjuvant treatment) and DNG (maintenance therapy) represents a safe and effective short‐term therapy after uterus‐sparing surgery for adenomyosis.
Synopsis
Maintenance DNG therapy following adjuvant GnRH‐a treatment after uterus‐sparing surgery was identified as an effective therapy for symptom control and prevention of recurrent adenomyosis.</description><subject>adenomyoma</subject><subject>adenomyosis</subject><subject>Adenomyosis - drug therapy</subject><subject>Adenomyosis - surgery</subject><subject>dienogest</subject><subject>Female</subject><subject>GnRH agonist</subject><subject>Gonadotropin-Releasing Hormone</subject><subject>Humans</subject><subject>maintenance therapy</subject><subject>Retrospective Studies</subject><subject>Uterus - surgery</subject><subject>uterus‐sparing surgery</subject><issn>0020-7292</issn><issn>1879-3479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFu1TAURS0Eop-WCQtAHiKkFNuJ4x9mVQWlqFUnnUev9kvqr8QOttMqM5bATthTV1KHXzqsLNmDd-6x5UvIB86OOWPii931_phXdSlfkQ3fqqYoK9W8Jps8ZIUSjTgg72LcMca44vwtOShrKZSoyw35ewnWJXTgNFJj0fkeY6LpFgNMC-38MPh763oKZjffgUu09w6MT8FP1j38_hNwQIgrcevD6B1SyIRdHQEhjZgj0CUMdM7bHHMkThDWQJxDj2Gh1mV7vnlcfLTxKz2hAbM_TqiTvUOqfVYnGtNsliPypoMh4vun85Bcf_92ffqjuLg6Oz89uSh0KRpZNAiodaVMXlJuBSrTlZWWzQ0KAXVTYZ5gBZ02ghkjaxAIsoG6VtuqbspD8mmvnYL_NecfaUcbNQ4DOPRzbEW2SrXlqs7o5z2q85NjwK6dgh0hLC1n7dpPu_bT_usnwx-fvPPNiOYZ_V9IBvgeuLcDLi-o2vOfZ1d76SPaD6R6</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Chan, I‐San</creator><creator>Hsu, Teh‐Fu</creator><creator>Shih, Ying‐Chu</creator><creator>Chang, Yen‐Hou</creator><creator>Wang, Peng‐Hui</creator><creator>Chen, Yi‐Jen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6074-5915</orcidid><orcidid>https://orcid.org/0000-0002-6048-8541</orcidid><orcidid>https://orcid.org/0000-0002-2982-4500</orcidid></search><sort><creationdate>202306</creationdate><title>Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study</title><author>Chan, I‐San ; Hsu, Teh‐Fu ; Shih, Ying‐Chu ; Chang, Yen‐Hou ; Wang, Peng‐Hui ; Chen, Yi‐Jen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3295-9eaecc47d7d75582e7df34c59be22a694ed7de4afcd20dd56a2ea59a66784693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>adenomyoma</topic><topic>adenomyosis</topic><topic>Adenomyosis - drug therapy</topic><topic>Adenomyosis - surgery</topic><topic>dienogest</topic><topic>Female</topic><topic>GnRH agonist</topic><topic>Gonadotropin-Releasing Hormone</topic><topic>Humans</topic><topic>maintenance therapy</topic><topic>Retrospective Studies</topic><topic>Uterus - surgery</topic><topic>uterus‐sparing surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, I‐San</creatorcontrib><creatorcontrib>Hsu, Teh‐Fu</creatorcontrib><creatorcontrib>Shih, Ying‐Chu</creatorcontrib><creatorcontrib>Chang, Yen‐Hou</creatorcontrib><creatorcontrib>Wang, Peng‐Hui</creatorcontrib><creatorcontrib>Chen, Yi‐Jen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, I‐San</au><au>Hsu, Teh‐Fu</au><au>Shih, Ying‐Chu</au><au>Chang, Yen‐Hou</au><au>Wang, Peng‐Hui</au><au>Chen, Yi‐Jen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study</atitle><jtitle>International journal of gynecology and obstetrics</jtitle><addtitle>Int J Gynaecol Obstet</addtitle><date>2023-06</date><risdate>2023</risdate><volume>161</volume><issue>3</issue><spage>751</spage><epage>759</epage><pages>751-759</pages><issn>0020-7292</issn><eissn>1879-3479</eissn><abstract>Objective
To investigate the safety and efficacy of adjuvant gonadotropin‐releasing hormone agonist (GnRH‐a) treatment followed by maintenance dienogest (DNG) therapy after uterus‐sparing surgery.
Methods
Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus‐sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty‐six patients (control group) received adjuvant 6‐month GnRH‐a therapy alone after uterus‐sparing surgery, and 44 patients (maintenance group) received postoperative 6‐month GnRH‐a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow‐up period was 18 months. The study was analyzed using generalized estimating equations.
Results
At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P < 0.001), hemoglobin level (P = 0.004), and uterine volume (P = 0.004) from baseline to 18 months after uterus‐sparing surgery. The symptom recurrence rate was significantly lower in the maintenance group than in the control group (4.6% vs. 37.0%, P < 0.001).
Conclusions
The findings of this study suggest that combinatorial treatment with GnRH‐a (adjuvant treatment) and DNG (maintenance therapy) represents a safe and effective short‐term therapy after uterus‐sparing surgery for adenomyosis.
Synopsis
Maintenance DNG therapy following adjuvant GnRH‐a treatment after uterus‐sparing surgery was identified as an effective therapy for symptom control and prevention of recurrent adenomyosis.</abstract><cop>United States</cop><pmid>36527263</pmid><doi>10.1002/ijgo.14635</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6074-5915</orcidid><orcidid>https://orcid.org/0000-0002-6048-8541</orcidid><orcidid>https://orcid.org/0000-0002-2982-4500</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7292 |
| ispartof | International journal of gynecology and obstetrics, 2023-06, Vol.161 (3), p.751-759 |
| issn | 0020-7292 1879-3479 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2755578176 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | adenomyoma adenomyosis Adenomyosis - drug therapy Adenomyosis - surgery dienogest Female GnRH agonist Gonadotropin-Releasing Hormone Humans maintenance therapy Retrospective Studies Uterus - surgery uterus‐sparing surgery |
| title | Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintenance%20dienogest%20therapy%20following%20adjuvant%20gonadotropin%E2%80%90releasing%20hormone%20agonist%20treatment%20after%20uterus%E2%80%90sparing%20surgery%20in%20adenomyosis:%20A%20retrospective%20cohort%20study&rft.jtitle=International%20journal%20of%20gynecology%20and%20obstetrics&rft.au=Chan,%20I%E2%80%90San&rft.date=2023-06&rft.volume=161&rft.issue=3&rft.spage=751&rft.epage=759&rft.pages=751-759&rft.issn=0020-7292&rft.eissn=1879-3479&rft_id=info:doi/10.1002/ijgo.14635&rft_dat=%3Cproquest_cross%3E2755578176%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2755578176&rft_id=info:pmid/36527263&rfr_iscdi=true |